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Mitochondria play multifaceted roles in malignant tumor progression. Beyond their
bioenergetic role, mitochondria are essential for providing malignant cells a higher
plasticity to face the harsh environmental conditions. Cell-autonomous metabolic
deregulation of cancer cells, or metabolic adaptation to microenvironmental cues (lack
of nutrients, stromal supply, hypoxia, etc.), represent the triggering event of mitochondria
overexploitation to orchestrate nutrient sensing and upload, signaling, and redox circuits.
As readout of their higher function, mitochondria produce high amounts of reactive
oxygen species (ROS) that are functional for multiple signaling networks underlying
tumor proliferation, survival, and metastatic process. To compensate for the higher rate
of mitochondrial ROS production, cancer cells have evolved adaptive mechanisms to
increase their antioxidant systems and to address ROS activating pathways useful for
the tumor cell adaptation to environmental changes. As these properties are critical for
cancer progression, mitochondrial ROS have recently become an attractive target for
anti-cancer therapies. We discuss how understanding of mitochondrial function in the
tumor-specific generation of ROS will impact on the development of novel redox-based
targeted therapeutic strategies.
Keywords: mitochondria, ROS—reactive oxygen species, tumormicroenviroment, anti oxidant, anticancer activity,
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INTRODUCTION
Mitochondrial ROS: Source and Regulation in Cancer
Tumor cells exhibit metabolic plasticity that provides them with a selective advantage to face
harsh microenvironmental conditions (e.g., hypoxia, acidosis, low nutrients availability). Beyond
the Warburg effect (i.e., high upload of glucose and its conversion into lactate nevertheless of
oxygen availability), tumor cells can use several nutrients to fuel mitochondrial metabolism and
support growth. Indeed, within the tumor cell, mitochondria represent dynamic organelles that
orchestrate a variety of signals, able to meet and finely adjust the fluctuating metabolic needs of
the cell. In this scenario, mitochondria promote the anabolic and catabolic machinery of a tumor
cell by driving fatty acid oxidation (FAO), TCA cycling, the electron transport chain (ETC) and to
provide intermediates to synthesize macromolecular building blocks such as amino acids, lipids,
nucleotides, and iron sulfur clusters, as well as reducing agent (NADPH) for their antioxidant
systems, respectively.
Reactive oxygen species (ROS) represent highly reactive molecules resulting from oxygen (O2)
including radicals and non-radicals, produced inside the cells through a high metabolic activity
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consuming oxygen. Therefore, at higher levels, ROS are
responsible for the damage of most of cellular macromolecules,
whereas they exhibit signaling role at moderate levels. As
by-product of intense oxidative phosphorylation (OXPHOS),
mitochondria specifically generate mitochondrial ROS (mROS).
ETC complexes I and III by leaking free electrons lead to a
mono-electronic O2 reduction to superoxide (O2•-), which is
readily reduced by superoxide dismutases (SODs) to hydrogen
peroxide (H2O2). The current idea is that cancer cells manifest
a peculiar pattern of high ROS levels than non-transformed
cells following the action of oncogenes, the loss-of-function of
most tumor suppressor genes, the deregulation of metabolism,
mitochondrial dysfunction, inflammatory burst, or genotoxic
stress (1) and this is counteracted by a strong and highly
regulated antioxidant machinery. mROS are counteracted by
a compartmentalized antioxidant apparatus not linked to the
cytosolic one (2), with mitochondria using their own antioxidant
enzymes, such as glutathione reductases, catalases, peroxidases,
and other NADPH-generating sources.
The main transcriptional response underlying the antioxidant
action in tumor cells is due to the activation of nuclear factor
(erythroid-derived 2)-like 2 (NRF2) (3). NRF2 is tightly and
positively regulated upon the inhibition of Kelch-like ECH-
associated protein 1 (KEAP1) and thus NRF2 stabilization
promotes the transcription of genes coding for antioxidants
enzymes. NRF2-KEAP1 canonical pathway is regulated by the
high ROS levels increased within the cell. In this setting, oxidants
induce the modification of specific cysteines on Keap1 structure
leading to the loss of basal cytosolic sequestration and the
ubiquitination of Nrf2. This results in Nrf2 translocation into
the nucleus to induce the transcription of antioxidant genes
(3). Also, a ROS-independent Nrf2 activation has been found
upon the activity of p62, a marker of cellular stress. p62 binds
to Keap1, thereby preventing Keap1-mediated trapping of Nrf2,
thereby inducing Nrf2 stabilization and activation (4). Balancing
ROS initiation and ROS scavenging allows cancer cells to achieve
and manipulate ROS within a certain sub-toxic tumorigenic
range. Enhancement or disruption of antioxidant capacities
can be beneficial or detrimental for tumor cells, respectively,
as it can prevent or not ROS from reaching cytotoxic levels.
Consequently, the finely-tuned ROS generation and scavenging
are two aspects fundamental to cancer cells since ROS-mediated
cell signaling can significantly impact on a wide range of cellular
pathways, including tumor initiation and proliferation, survival,
de-differentiation, and metastatization.
EFFECTS OF CELL-AUTONOMOUS
MITOCHONDRIAL ROS ON TUMOR
PROGRESSION
Inactivation of tumor suppressor genes, as well as activity
of oncogenes and mitochondrial DNA (mtDNA) mutations,
are cell-autonomous mechanisms, somehow regulated by and
regulating tumor ROS. However, these mechanisms underlying
activation of mitochondrial ROS generation can be associated
to a rewiring of the mitochondrial metabolism of tumor
cells [e.g., MYC/KRAS or MYC/ERBB2 ablation in breast and
pancreas cancer cells (5–7)]. Such metabolic remodeling reflects
the genetic and environmental landscape of a cancer cell in
given circumstances.
Effect of mROS on Tumor Initiation and
Progression
Mitochondria may contribute to malignant phenotype as mROS
can lead to DNA aberrations and activation of oncogenic
pathways. Mutations in mtDNA-encoding ETC have been
investigated in several tumor models as prone to confer a
selective advantage in tumor initiation. Indeed, mROS derived
from mutated complex I is crucial for the tumor formation in
vivo (8). Conversely, loss-of-functionmutations ofmitochondrial
transcription factor A (TFAM), which participates to the
replication of mitochondrial genome, are incompatible with
tumor formation in vivo (9), while heterozygosity for TFAM
is crucial for a ROS-dependent intestinal tumorigenesis (10).
Interestingly, the seminal study by Ishikawa et al. explored
the pro-metastatic role of exogenous mtDNA acquired by
recipient cancer cells with low propensity to metastatize. The
acquisition of mtDNA confers high metastatic potential via
the overproduction of mROS derived by mtDNA-transmitted
complex I mutation and the up-regulation of nuclear genes
such as HIF-1α, VEGF, and MCL-1 (myeloid leukemia cell
protein-1) involved in metastasis (11). However, ROS-mediated
DNA damage promotes genomic instability in gliomas models,
particularly by mediating the deletion or mutation of tumor
suppressor genes such as TP53, a driver for maintaining
functional antioxidant defenses (12). Finally, subsets of breast
cancer cells derived from primary tumors have been shown to
display differential mROS content. High mROS-loading cells
activate mitochondrial unfolded protein response (UPRmt) and
its activation regulates cytoprotective mechanisms in a SIRT3-
dependent manner, resulting in mitochondrial rewiring as well
as in resistance to subsequent oxidative stress (mitohormesis, i.e.,
the activation of cytoprotective mechanisms such as the unfolded
protein response, important for improving the cellular resistance
to mitochondrial stresses). As phenotypic readout, mitohormesis
primes this subpopulation to be highly metastatic compared
to low mROS-producing cells, as metastasis, angiogenesis, and
cell migration gene sets are positively enriched in UPRmt−HIGH
patients (13).
Effect of mROS on Tumor Energy
Metabolism
Furthermore, mutations of specific TCA cycle enzymes such
as succinate dehydrogenase (SDH), fumarate hydratase (FH),
and isocitrate dehydrogenase (IDH) may dramatically alter
cell bioenergetics and consequently the ROS production. SDH
complexes—(e.g., Sdhb, SdhC, and SdhD), when inactivated,
have been addressed as factors leading tumorigenesis via mROS.
Particularly, the pharmacological or genetic impairment of
specific subunits of SdhB, increases superoxide production,
increases HIF-α stabilization in an ROS-dependent manner,
and this has a positive impact on the growth rates in vitro
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and in vivo (14). FH alterations observed in models of
hereditary leiomyomatosis and renal cell cancer promotes the
accumulation of fumarate able to load a succination reaction
on the glutathione to produce the metabolite succinated
glutathione (GSF) and Keap1 (15). Thus, GSF acts as a NADPH-
consuming metabolite used by glutathione reductase, thus
reducing antioxidant capacity and resulting in increased mROS
that, maintained in homeostatic levels by the simultaneous
activation of Nrf2, promote tumorigenic signaling. Also,
alterations in IDH1/2 may cause not only the complete loss
of wild-type enzymatic functions, but also an increase in ROS
levels due to the impaired action of NADPH and GSH (16).
Overall, choked TCA cycle and/or OXPHOS are functional
for ROS generation. Mechanistically the alterations in these
key TCA cycle enzymes provoke metabolic perturbations (e.g.,
succinate and/or fumarate accumulation) leading to signaling
cascades suchHIF1 activation (17, 18). Besides thesemechanisms
involving TCA intermediates-dependent inhibition of HIF-
degradation-mediating enzymes such as prolyl hydroxylases, also
ROS derived by the overexploitation of mitochondria can trigger
HIF1 stabilization. So far, while mROS generation from complex
I is predominantly located into mitochondrial matrix, complex
III is capable of producing ROS able to act as signaling molecules
upon diffusion into cytosol. These mROS can oxidize some
cysteines in prolyl hydrozylase 2 (PHD2), affecting its enzymatic
activity and thus allowing for the stabilization and the subsequent
activation of HIF1α and HIF-induced genes, respectively (19).
Effect of mROS on Tumor Stemness
As tumor expansion is a feature strictly related to the ability of a
malignant cell to display tumor-initiating and de-differentiating
potential (stemness), regulation of ROS levels is useful for
cancer stem cells (CSCs) to elicit their hallmark features.
However, CSCs are highly heterogeneous in their metabolic
and redox profiles. Different mitochondrial exploitation and
consequently mROS generation has been addressed in different
models. Accordingly, in liver CSCs the stemness marker
NANOG, upon activation of Toll-like receptor 4 (TLR4)-E2F1
axis, negatively impacts on mitochondrial respiration and ROS
generation (20). Similarly, in acute myeloid leukemia, mROSlow
CSCs are paradoxically OXPHOS-dependent and overexpress
Bcl-2. Interestingly, Bcl-2 inhibition eradicates the quiescent
stem cells by increasing mROS. Conversely, ovarian CSCs
privilege OXPHOS metabolism and mROS production sustains
this phenotype (21). Additionally, in other models of CSCs,
mROS due to high lipid catabolism trigger the activation of
MAPK as well as of epithelial-mesenchymal transition (EMT),
consequently potentiating cancer invasion and metastasis (22).
Notably, in breast cancer, a high plasticity in determining cellular
stem-like states results in two distinct metabolic profiles of
stem cell sub-populations. While mesenchymal-like breast CSCs
undergo a typical Warburg metabolism but repress ROS to
sustain their stemness status, the epithelial-like ones are highly
respiratory and show high OXPHOS-dependent ROS. Also,
pancreatic cancer stem cells surviving to KRAS ablation rely on
mitochondrial metabolism and show increased mROS levels (5).
Furthermore, CSCs relying on mitochondrial metabolic rewiring
frequently are responsible of tumor relapse and acquire resistance
to chemotherapies and other treatments (23). Accordingly, the
levels of mitochondria-derived ROS are presumably functional
for the maintenance of resistant phenotype.
Effect of mROS on Tumor Chemosensitivity
The modulation of mitochondrial redox state exerts different
roles in the chemoresistance scenario, thereby reflecting the
high heterogeneity and plasticity of cancer cells. Indeed,
negative regulation of mitochondrial gene transcription by
mitomiRNA-2392 is coupled with increased mROS levels as
well as chemosensitivity profile of resistant squamous cell
carcinoma cells (24). Also, persistent oxidative stress leads to
the accumulation of promyelocytic leukemia protein (PML)-
nuclear bodies in ovarian carcinomas, resulting in activation
of the transcriptional co-activator PPARγ coactivator-1α (PGC-
1α). Active PGC-1α-mitochondrial respiration axis results in
high mROS content in these cells as well as alterations
in iron homeostasis. In keeping, high ROS levels represent
a key element in the modulation of the chemosensitivity
of high-OXPHOS cancer cells. Indeed, high-OXPHOS cells
exhibit increased response to conventional chemotherapies,
and PML silencing is able to reduce the sensitivity of high-
OXPHOS cells to a ferroptosis drug such as ironomycin,
thereby showing that this sensitivity is linked to PML and
OXPHOS status (25). Also, MYC activation cooperatively
with myeloid cell leukemia-1 protein has been reported to
sustain the mitochondrial upgrading in terms of biogenesis
and respiration of chemotherapy-resistant CSCs in triple
negative breast cancer. The increase of mitochondrial respiration
and mROS production lead to HIF1-dependent expansion of
resistant CSCs (26). Similarly, resistant clones of pancreatic
CSCs—showing OXPHOS dependency and high antioxidant
properties—emerged during OXPHOS inhibition treatment rely
on MYC activation as a metabolic switcher, by regulating
the transition from a PGC-1α-dependent strong mitochondrial
activity toward an intermediate glycolytic/respiratory phenotype
culminating in high mROS content (27).
EFFECTS OF CELL NON-AUTONOMOUS
MITOCHONDRIAL ROS ON TUMOR
PROGRESSION
It has been largely recognized that mitochondria exhibit
a multifaceted role in triggering and orchestrating cellular
responses to environmental stimuli and signals derived by
hypoxic conditions and/or stromal cells, thereby regulating,
among others, cell non-autonomous mROS production. The
microenvironment in the primary tumor primes the cancer cells
to remodel their metabolism to permit the escape from it and the
metastatization in distant organs.
Effect of mROS on Tumor Metastatization
Metastatization depends on the ability of tumor cell to
survive detachment from the extracellular matrix and
subsequently undergo intravasation. Loss of attachment
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provokes mitochondrial alterations in cancer cells. Indeed, cells
detached from the matrix undergo metabolic reprogramming
by upregulating pyruvate dehydrogenase (PDH) kinase, thereby
attenuating the flux of glycolytic carbon (i.e., pyruvate) into
mitochondrial oxidation, ultimately affecting the mitochondria
functionality and ATP levels (28, 29). Recently, anchorage-
deprived tumor cells have been shown to rely on a metabolic
phenotype based on reductive carboxylation of glutamine,
which supports the production of mitochondrial NADPH
useful to combat mROS (30). However, the induction of a
hypoxic-dependent cell clustering induction has been shown
to mediate mitophagy able to clear damaged mitochondria
and limit mROS burst, thereby supporting tumor cell survival
during extracellular matrix detachment and metastatic spread
(31). The management of mitochondrial ROS levels is a key
feature of acute myeloid leukemia, where the protein kinase-ε
activation controls the content of mROS by impacting on some
ROS-buffering enzymes, such as thioredoxin and glutathione
synthetase, thereby promoting the tumor progression in
vivo (32). Importantly, modulation of antioxidant defense
against mROS has been reported to be crucial for metastatic
cancer cells. Indeed, it has been reported that one-carbon
metabolism maintains the mitochondrial redox homeostasis
during hypoxic conditions. Indeed, mitochondrial serine
hydroxymethyltransferase (SHMT2) is induced in hypoxic
conditions and its activity results in a high NAPDH-dependent
mROS balance, as the methyl donor methylene-tetrahydrofolate
can be oxidized through the folate metabolic enzymes to
generate NADPH, which is important for maintaining cellular
redox balance (33). Also, circulating and secondary sites-
engrafted cancer cells displayed higher levels mROS than
those isolated from the primary melanomas. However, upon
metastatic dissemination, melanoma cells rely on folate
pathway for the capacity to exploit folate-derived NADPH to
neutralize oxidative stress (34). In apparent contrast, Porporato
et al. have shown that metastatic colonization is sustained
by superoxide derived by dysfunctional mitochondria. In
particular, mROS are able to target and activate Src-Pyk
molecular axis underlying the migration machinery of cancer
cells (35) and pharmacological scavenging of mitochondrial
superoxide prevent metastatic dissemination. In this scenario,
the mitochondrial reprogramming is often associated with the
activation of PGC-1α, a transcriptional regulator mitochondrial
biogenesis and oxidative metabolism. However, it is reported that
PGC-1α increases mitochondrial respiration in melanoma cells
and, at the same time, helps them to manage the oxidative stress
by orchestrating the activation of ROS-detoxification systems
such as glutathione (36) and thus sustaining tumor growth.
Conversely, PGC-1α overexpression impairs prostate and renal
cancer progression (37, 38). Thus, the role of PGC-1α in the
management of both the mitochondrial dynamics/functionality
and redox biology (i.e., upregulation of SOD2, Nrf2, and GSH)—
beneficial or detrimental for the tumor progression—seems
to be paradoxical; however, it reflects the tumor metabolic
heterogeneity and new insights on the impact of the spatio-
temporal tuning of fluctuations of mROS levels on cancer cell
state need further investigations.
Metastatic dissemination and tumor formation and growth
are well-known hallmarks enabled and sustained through
contributions from multiple repertoires of stromal cell types.
Particularly, rewiring of mitochondrial metabolism has been
extensively affected by tumor stroma (39). By expanding
Ishikawa’s findings, it has been shown that in vivo horizontal
transfer of intact mitochondria from stromal compartment
in the host animal to the mitochondria-depleted melanoma
tumor results in a renewed OXPHOS and tumorigenic
capacity in the mitochondria-deficient recipient cells (40).
The incorporation of host mitochondria can reasonably have
an impact on the levels of mROS, newly exploitable as
tumorigenic signals. In addition, a metabolic cross-talk driven
by lactate derived by cancer-associated fibroblasts promotes
a mitochondrial exploitation in prostate carcinoma cells.
Consequently, lactate-driven mROS burst is essential for EMT
engagement and invasiveness of these stromal-reprogrammed
cancer cells. Also, mROS are able to oxidize Src and
pyruvate kinase-M2, key molecules in the establishment and
maintenance of the metabolic loop (41, 42). At the same
time, mitochondrial redox dynamics underlies the shaping
of the tumor microenvironment promoted by stromal cells.
Mitochondria dysfunction in fibroblasts induced by long-term
radiation induces mROS increased levels. These activate TGFβ
signaling which in turn mediate the expression of α-SMA, a key
marker of the fibroblast reactivity indispensable for the tumor
growth (43).
Effect of mROS on Tumor Immune
Environment
The control of mitochondria-derived ROS has been increasingly
explored as a driver of the recruitment and the activation of
immune cells in tumor environment. It has been observed
that cancer patients show inactive subsets of immune cells
and their neutrophils show higher OXPHOS metabolism (44).
Indeed, neutrophils maintain NADPH-oxidase-dependent ROS
production, under glucose starvation, through balancing with
NADPH levels supplied by fatty acids oxidation. This strategy is
important for neutrophils to overcome the nutritional limitations
occurred in the glucose-deprived tumor microenvironment,
where mitochondria is exploited and functional for promoting
neutrophil activation and the inhibition of the adaptive anti-
tumor immune responses (44). Also, regulatory T cells (Tregs)
are committed to survive and proliferate in such a hostile milieu
like tumor microenvironment because they display and exploit
both glycolysis and fatty acid synthesis/oxidation, allowing them
to predominate over CD4/CD8+ T cells mainly relying on
the glycolysis (45). In keeping, the suppression of OXPHOS
through complex I inhibitor such as metformin is detrimental
for tumor-infiltrating Treg cells differentiation from T naïve
cells, probably acting on mROS content (46). To note, Treg
cells require a functional mitochondrial complex III to maintain
their suppressive function, suggesting a fascinating role of
mROS in the metabolic and epigenetic landscape of Treg
cell compartment (47). Interestingly, ovarian-cancer-infiltrating
Treg cells showing high OXPHOS dependency produce higher
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amounts of mitochondrial ROS and undergo apoptosis, thereby
mediating the local production of immunosuppressive molecules
able to act on other immune cell types and, consequently,
a higher immune escape of tumors and failure of the
clinical approach involving Treg depletion (48). To note, high
exploitation of glucose by cancer cells results in a glucose-
deprived microenvironment, leading to the establishment of a
metabolic competition between tumor and immune cells (49),
resulting in a T cell mitochondrial dysfunction and repression
(50). In such metabolic scenario, CD8+ tumor-infiltrating cells
have been characterized to be unable to efficiently uptake
glucose and to have hyperpolarized, fragmented mitochondria
generating large amounts of mROS, otherwise required for
CD4+ T cell activation (51). These defects in glucose uptake
and glycolysis as well as in mitochondrial dynamics and
function contribute to the failure of CD8+ T cell activation
and exhaustion state in the microenvironment, where the renal
carcinoma cells are highly glucose- consuming and depriving
(52). Accordingly, in glucose-deprived conditions, tumor cells
utilize mitochondria as glucose sensor by increasing mROS-
dependent oxidative stress and post-translationally regulating the
expression of monocarboxylate transporter 1, whose functional
activity of lactate transport is dependent on pH gradient.
This response as result of mitochondrial dysfunction drives
the migration of cancer cells conferring them the ability to
evade a glucose-depleted environment (53). mROS as well
as other mitochondrial-associated metabolites critically impact
on the effector pro- and anti-inflammatory functions of M1
and M2 macrophages, respectively (17). Indeed, M1 and M2
macrophages differ significantly in the major pathways of
energy utilization and provision. However, mROS function is
controversial in these cells. It has been shown that complex I-
derived ROS are bactericidal and activate the inflammosome
in M1 macrophages (54). On the other hand, mROS activate
the NF-κB-dependent recruitment and polarization of M2
macrophages (55), although in non-tumoral circumstances. It
is likely that, in the tumor microenvironment, macrophages
undergo mitochondrial adaptations according to the nutrient
availability (and mROS levels change, accordingly). For example,
lactate, highly enriched in the tumor environment, shows a
polarizing effect on M1 macrophages toward the M2 pro-tumor
phenotype (56) and the HIF1-associated signaling cascade is
presumably modulated also upon a renewed lactate-dependent
mitochondrial redox state. In keeping, high levels of mROS
promote pro-invasive signature of melanoma-associated M2
macrophages by regulating their tumor necrosis factor α
secretion (57). Finally, in the complex immune environment,
the dendritic cells (DCs) are responsible for the antigen
presentation, which is crucial for the activation and the
recruitment of CD8+ anti-tumor T-cell population. Recently,
the reduced mROS levels in DCs impair their ability in cross-
presentation and, consequently, in the culminating anti-tumor
effect mediated by CD8+ T-cell response in vivo (58), suggesting
a potential role of mROS in modulating protective immunity
against tumor.
Mitochondrial redox homeostasis crucially impacts on tumor
cells behavior and regulates several hallmarks of cancer. Altered
mitochondrial metabolism due to genetic dysfunction and/or
microenvironmental signals provides a scenario where cancer
and cancer-accessory cells need to exploit and maintain a specific
threshold for compartmentalized mROS levels to orchestrate
mROS-dependent signaling machinery during the tumor
progression (Figure 1). However, the compartmentalization of
the ROS generated and localized in the mitochondria in tumor
and/or stromal cells provides a challenging issue to target and
reduce mROS by an anti-tumoral perspective.
TARGETING MITOCHONDRIAL REDOX
CAPACITY
The several crucial functions of mitochondrial redox activity in
tumor progression and in the advanced stages of cancer, making
them a suitable choice for anti-tumor treatment. Methods that
address mitochondrial metabolism has been demonstrated to
be active in various clinical cancer researches and extensively
studied in Weinberg and Chandel (59). Despite the fact that
some tumor cells increase their production of ROS, other tumor
cell lines involve antioxidant systems to ensure that ROS levels
do not attain a dangerous point. It is not unexpected that the
cure of cancer with antioxidants has been favorable in a few
studies, while unsuccessful in others. Vitamin C increases the
power of the anti-proliferative role of doxorubicin in breast
tumor (60), whereas high vitamin D levels are pertinent with
a higher survival rate in patients with colorectal cancer (61).
Therapy with carotenoids could increase fatality in breast cancer
patients (62) whereas treating the same patients with vitamin C
and E has been associated with a good overall survival (62). It
may be deduced that the dietary antioxidants fail because they
do not attain the restricted ROS produced by the mitochondria
(59). The dual behavior of mROS shows that they can both assist
or limit tumor initiation and growth. Therefore, mitochondrial
antioxidant and pro-oxidant strategies have been considered for
anti-cancer treatments (Table 1).
Mitochondrial Antioxidant Strategies
Targeting specific mROS with the improvement of the
production of antioxidants targeted to specific subcellular
compartments (63) represent potential advances for antioxidant
cancer therapies. Many approaches of mitochondria-directed
pharmaceutical administration have newly been developed.
One of these methods utilize de-localized lipophilic cations
(DLCs), which are specific for mitochondrial negative charge
matrix and pass the membranes of mitochondria (64, 65).
Specific antioxidants that are targets of mitochondria (MTAs),
including MitoQ, MitoTEMPO, and SkFQs, are noted to pass
all biological membranes and collect inside mitochondria easier
than their non-targeted parent antioxidants [due to its link
to triphenylphosphonium (TPP)], rendering them effective in
guarding against mitochondrial oxidative damage (64).
MitoQ
One of the most studied antioxidant molecules that target
mitochondria is MitoQ (mitoquinone). It consists of TPP
covalently liked to the ubiquinone moiety of the endogenous
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FIGURE 1 | Cell autonomous and cell non-autonomous mechanisms impact on the mitochondrial ROS (mROS) production and management in cancer cells.
antioxidant coenzyme Q10 (CoQ10) by a ten-carbon aliphatic
chain. MitoQ distinctly reduces proliferation of diverse
melanoma xenograft models of carcinogenesis (35). MitoQ,
impedes the advancement of spontaneous metastasis of
tumorigenic MDA-MB-231 human breast cancer cells embedded
orthotopically, in the mouse mammary fat pad (69).
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TABLE 1 | Drugs targeting mitochondrial redox capacity.
Drug Mechanism of action References
MitoQ Antioxidant that target mitochondria. The antioxidant properties of quinone are combined
with the lipophilic cation TPP.
(63, 64)
MitoTEMPO Antioxidant that target mitochondria. The antioxidant properties of piperidine nitroxide
(Tempo) are combined with the lipophilic cation TPP.
(63–65)
SkQ1 Antioxidant that target mitochondria. The antioxidant properties of plastoquinone are
combined with the lipophilic cation TPP.
(63, 66)
Phenformin Mitochondrial respiration inhibitor that block the mitochondrial complex I. (67)
Mito-metformin Mitochondrial targeted metformin. Mitochondrial respiration inhibitor that block the
mitochondrial complex I.
(67, 68)
MitoVitE This compound is made by α-tocopherol attached to TPP. Inhibitor of complex I-mediated
mitochondrial respiration.
(63–65)
MitoChM Mitochondria-targeted vitamin E analog. Mitochondria-targeted antioxidant. (69)
MitoChM-Ac MitoCh analog. Mitochondria-targeted antioxidant. (69)
Mito-CP Inhibits complex I-mediated mitochondrial respiration. (70)
Mito-CP-Ac Mito-CP analog. Inhibits complex I-mediated mitochondrial respiration. (70)
Menadione-Ascorbate Mitochondria-targeted pro-oxidant. (71)
B-phenylethylisothiocyanate (PEITC) Mitochondria-targeted pro-oxidant. (71)
ME-344 Strong mitochondrial OXPHOS complex I inhibitor. (67)
MitoVES α-tocopheryl succinate with improved efficacy. Block the mitochondrial complex II, leading
to generation of ROS.
(72)
Dichloroacetate (DCA) Antioxidant that target mitochondria. (73)
MitoTEMPO
Another TPP derivative is MitoTEMPO, however it is associated
with the stable piperidine nitroxide radical TEMPO, which
obtains an electron from hydroxylamine a strong radical
scavenger. MitoTEMPO can also function as a cytosolic
superoxide dismutase (SOD) mimetic, which transforms
superoxide into water and enables ferrous iron to be oxidized
into ferric iron. MitoTEMPO inhibits melanoma cell growth,
reduces melanoma cell viability, and induces apoptosis, but does
not affect non-malignant skin fibroblasts (35, 69). Diminished
mROS production in mitoTEMPO treated-melanoma cells
modifies cell signaling mediated by mROS-sensitive Akt,
ERK1/2, and HIF1-α and decreases xenograft growth in
mice (74).
SkFQs
A different group of mitochondria targeted antioxidants named
“SkFQs” was created by Skulachev et al. utilizing plastoquinone to
change the ubiquinone antioxidant moiety of MitoQ (66). One of
the greatest investigated “Sk” molecules is the compound named
SkQ1, which is a TPP derivative associated with plastoquinone
itself. Tumor growth of rhabdomyosarcoma xenograft in nude
mouse model was suppressed by SkQ1. SkQ1 blocked the growth
of fibrosarcoma HT1080 and RD tumor cells in culture due to the
inactivation of Aurora family kinases (75).
Mitochondrial Pro-oxidant Strategies
A different anti-tumor redox approach lies in selectively
activating mitochondrial oxidative stress in tumor cells by
benefitting of their commonly higher mROS levels and abundant
antioxidant defense strategy.
Mito-Metformin
Drugs for oxidative phosphorylation inhibition like Mito-
metformin are able to decrease mitochondrial respiration thanks
to its action on the activity of electron transport chain
complex I. An interesting proof of action of such molecule
has been investigated in pancreatic ductal adenocarcinoma,
where Mito-metformin inhibits cancer cell proliferation by
enhancing the formation of superoxide and other oxidants,
presumably acting on AMPK which, in turn, leads to the ATP
depletion and growth arrest. Although it still needs further
studies, it is conceivable that Mito-metformin acts via mROS-
AMPK axis on AKT/FOXO3/FOXM1 signaling pathway (68).
In cancer cells, Mito-metformin reduces hypoxic activation of
HIF1 with consequently reduction of cellular proliferation and
increase of cell death (76). Tumor cells conveying oncogenic
mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2)
presented heightened demand on oxidative metabolism and
their sensitivity to pharmacological inhibition of OXPHOS is
increased (77).
MitoVitE and ME-344
MitoVitE (mitotocopherol) consists of TPP adjoined to the
a-tocopherol moiety of vitamin E with two carbon chain.
MitoVitE debilitates mitochondrial complex I which results
in the leakage of electrons and production of mROS and
reduces the proliferation of MYC-dependent osteogenic sarcoma
cells (78). CSCs are defined by an extremely high plastic
metabolism, which in turn allows them to endure and
withstand stress circumstances by shifting between glycolysis
and OXPHOS (79). Hence, the pharmacological hindrance of
oxidative phosphorylation by mitochondrial targeting drugs
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may block this rescue system of CSCs and would make CSCs
more responsive to chemotherapeutics generated to kill the
glycolytic cancer cells with high rate of proliferation. Suppression
of glycolysis or blocking OXPHOS only has restricted effects
on cancer CSCs. The depletion of intracellular ATP (79)
occurs only through the combination of the direct targeting
of both pathways. A very powerful interdependent result able
to counter this resistance was accomplished by an alliance of
chemotherapeutics with the inhibitors of mitochondria complex
I ME-344 (67), which prevented the change to mitochondrial
dependent metabolism. The vitamin E analog, α-tocopheryl
succinate mitochondrial-targeted derivative (MitoVES), is a
promising mROS targeted anti-cancer drugs with the potential
to eliminate CSCs (72).
Mito-CP and Mito-CP-AC
Alternative anticancer redox strategies include the use of
synthetic mitochondria-targeted inhibitors of complex I, like
Mito-CP and Mito-CP-AC to inhibit tumor cell growth and
promote cancer cells apoptosis. Mito-CP and Mito-CP analog,
Mito-CP-Ac, that incorporate an acetamide group instead of
the nitride of Mito-CP, are 10-carbon side chain having a
nitride group that can operate stimulation mitochondrial ROS
through the inhibition of complex I. The synergism of both
Mito-CP and Mito-CP-Ac with 2-deoxy-glucose (2-DG) to
deplete intracellular ATP, prevent cell proliferation and cause
apoptosis in pancreatic cancer cells. Changing the mitochondrial
function and the intracellular citrate levels by mitochondrial
antioxidants Mito-CP and Mito-CP-Ac lead to a decline of cell
proliferation and the beginning of apoptosis in pancreatic cancer
cells (70).
Menadione-Ascorbate and
β-phenylethylisothiocyanate (PEITC)
Specific molecules that selectively induce mitochondrial
oxidative stress are under study. The Menadione-ascorbate
combination and PEITC are two promising compounds for
this particular purpose. Ascorbate improves menadione redox
capacity, advancing to the formation of intracellular mROS
(71). Growing the cells in the presence of both ascorbate,
menadione and aminotriazole, a catalase inhibitor, causes a great
diminishing of cell survival which strengthens the role of H2O2
as the principal oxidizing agent that kill K562 cells (80, 81). It was
demonstrated that in Bcr-Abl expressing hematopoietic cells and
in H-RasV12 mutated ovarian epithelial cells these oncogenic
transformation lead to mROS generation and contributes to
the malignant cells becoming highly sensitive to PEITC, which
completely cripples the glutathione antioxidant system and
causes severe mROS build-up preferentially in the cancer cells
due to their active mROS output (82).
Dichloroacetate (DCA)
DCA, a PDK1 inhibitor, is alternative antioxidant that target
mitochondria that causes an oxidative-dependent apoptosis in
multiple glioblastoma cell lines (73).
Alternative Mitochondrial ROS Targeted
Strategies
One Carbon Metabolism Targeting
In order to maintain various antioxidant defense systems,
NADPH is fundamental. The production of NADPH in the
mitochondria occurs from one carbon metabolism (83), and
one carbon metabolism in the mitochondria commences by
serine catabolism by serine hydroxymethyltransferase (SHMT2).
As indicated in a study, under hypoxia SHMT2 is basic for
mitochondrial redox balance in particularly in Myc-transformed
cells. This is a characteristic metabolic feature shared by many
tumors (33). It has been demonstrated that the reduction
of cellular NADPH:NADP+ ratio occurs in cells in which
SHMT2 knockdown was performed. In these cells, an increase
in hypoxia induced cell death is observed. As a result, the
tumor growth was reduced by diminishing SHTM2 (33). A
strong inhibition of hepatocellular carcinoma xenograft growth
using inducible shRNA against SHMT2 has been identified
(84). Cancer and normal cells show different expression of
methylenetetrahydrofolate dehydrogenase (MTHFD2), a crucial
enzyme in the mitochondrial one carbon metabolism (85). The
decrease of MTHFD2 leads to an increase of mROS levels
sensitizing cancer cells to oxidant-induced cell death, with no
effects on normal proliferating cells not expressing the enzyme
(85). These are the reasons MTHFD2 may symbolize a likely
mitochondrial redox anticancer therapeutic agent. In a murine
model of AML, blocking MTHFD2 by silencing with shRNA the
animals still succumbed to their disease (85).
Mitochondrial Redoxins Targeting
Some studies have found large presence of the antioxidants
thioredoxin reductase (TrxR), particularly the mitochondrial
thioredoxin (TrxR2), in various types of cancer and this
expression has been associated to tumor aggressiveness (86).
Similarly, mitochondrial glutaredoxin-2 (Grx2) has been shown
to have an anti-apoptotic outcome in cancer cells (87).
Additionally, it has been well-established that when glutathione
levels decrease in murine breast cancer do not hinder tumor
growth but rises Trx activity as a compensatory switch to buffer
mROS levels (88). The ability for cancer cells to withstand
and adapt to glutathione inhibition by enhancing antioxidant
functions of the mitochondria is conveyed in this last data.
Targeting TrxR2 had demonstrated to be beneficial in inhibiting
multiple myeloma growth by reducing the proteasome function
and enhancing cytotoxic oxidative stress (89). Furthermore, Grx2
down regulation may make cells more sensitive to the toxic
properties of chemotherapy agents (90).
Mitochondrial ROS Generators and PD-1
Immunotherapy
Cancer treatment has been completely influenced by
immunotherapy by PD-1 blockades through its long-lasting
effect and high efficacy against a wide variety of cancers with
limited antagonistic effects (91). Nevertheless, the percentage
of patients that still remain insensitive or less responsive to the
PD-1 blockade therapy is around 50%. To change and improve
upon this lack of response, PD-1 blockade therapy has joined
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with several other types of cures. Research has shown that
mROS generation by molecules that generate mROS (Luperox,
chaetocin phytol) or secondarily by uncouplers of mitochondria,
carbonylycyanide-p-trifluoromethoxphenylhydrazone (FCCP)
and 2, 4-Dinitrophenol (DNP), increases the cancer killing
activity of PD-1 blockade by growth of the effector or memory
CTLs in draining the lymph node (DLNs) and inside the
cancer tissues. It has been shown that tumor reactive cytotoxic
T lymphocytes (TR CTLs) treated with PD-L1 may bring
triggered mitochondria resulting in higher mROS production.
Furthermore, it was revealed that the administration of ROS
producers together with uncouplers has strong effects with
PD-1 blockade on tumor growth inhibition. The ability of
uncouplers to synergize the cytotoxic effects of PD-L1 therapy
may be due to their capacity to cause cellular mROS through
hypoxia (92).
Photo-Thermal and Photo-Dynamic Therapy
Two new strategies in mitochondrial targeting redox cancer
therapy are photo-thermal and photo-dynamic therapy. It is
possible to bind chemically gold, platinum, carbon, iron, titanium
oxide nanoparticles to organic compounds like cyanidines and
then connected to TPP, with the goal of selectively store within
mitochondria. These nanomaterials and molecules directly or
indirectly produce mROS when photo irradiated and this leads
to activation of apoptosis which may include mitophagy (93).
Some examples used in these therapies are Mito-CCy, mito-
CIO, protein-ruthenium hybrids, and FDA approved green
indocyanine (94, 95).
CONCLUDING REMARKS
A different method for curing and preventing cancer may lie
in mitochondrial redox based treatments, even in combination
with chemo and radio therapy. Nonetheless, there are many
aspects that influence the effectiveness of the treatment,
such as the micro-environment, the stage of the tumor, the
antioxidant specific mechanisms of action and the mROS
levels within the tumor. In conclusion, mROS and mROS
“scavenging” structures which simultaneously target the tumors,
may bring about anti-cancer responses thus overcoming
malignant transformation and further cancer growth. Reducing
the levels of mROS impedes the survival signaling, whereas
blocking the cancer’s cell antioxidant strategies causes cell
death. Therefore, in deciding whether to use a pro-oxidant
or anti-oxidant approach for tumor therapy, the definition of
a “redox signaling hallmark,” composed of various constraints
including the cell redox grade, definition of antioxidants, a
signature of cell signaling and transcription factor activation,may
be fundamental.
Mitochondrial redox signaling and management are crucial
for most hallmarks of cancer, such as initiation and growth,
anoikis resistance, stemness achievement, metastasization, and
establishment of an immunosuppressive environment. The
mROS-dependent effects on several hallmarks of cancer are
summarized in the specific boxes.
Cell autonomous include mutations and damage in ETC
complexes (Complex I and III) and in mtDNA, leading to a
dysfunctional mitochondria highly-producing ROS. Cancer cells
harboring mutations in specific TCA cycle enzymes display
high levels of mROS. Particularly, FH loss induces fumarate
accumulation leading to the succination of GSH and the
inactivation of Nrf2- antioxidant response. Nrf2 is a transcription
factor involved in the activation of the antioxidant response
to combat cytosolic and mitochondrial ROS, upon the release
of the repressive molecule Keap1 from Nrf2. In parallel, PGC-
1α is a multifunctional transcriptional coactivator controlling
mitochondrial dynamics and biogenesis as well as the anti-mROS
defense system.
Cell non-autonomous mechanisms involve the tumor cell
mitochondrial deregulation/overexploitation induced by stroma.
Stromal environment is capable to transfer mtDNA into tumor
cells, thus restoring respiration and amplifyingmROS-dependent
signaling. Also, damage such as radiation promotes mROS-
dependent activation of fibroblasts into CAFs, expressing a-
SMA. CAFs in turn produce high amount of lactate which—
upon imported in cancer cells—fuels TCA cycle (PGC-1α
activation is needed for this reprogramming), leading to high
levels of signaling-associated mROS, thereby activating Src/Pyk2,
Src/PKM2-dependent motility pathways and stabilizing HIF1.
Finally, tumor immune environment faces mROS in the
events of apoptosis and exhaustion of Treg and effector cells,
respectively, thus supporting the tumor immunosuppression.
Also, mROS levels are finely modulated for dendritic cells
antigen cross-presentation.
AUTHOR CONTRIBUTIONS
LI, EG, and MP wrote, elaborated the figure, and critically
reviewed the manuscript. PC and MP designed and
directed manuscript.
FUNDING
This work was supported by PRIN 2017 (grant to PC) and
Fondazione CR Firenze, AIRC (grant 19515 to PC).
REFERENCES
1. Sullivan LB, Chandel NS. Mitochondrial reactive oxygen species and cancer.
Cancer Metab. (2014) 2:17. doi: 10.1186/2049-3002-2-17
2. Costa NJ, Dahm CC, Hurrell F, Taylor ER, Murphy MP. Interactions of
mitochondrial thiols with nitric oxide. Antioxid Redox Signal. (2003) 5:291–
305. doi: 10.1089/152308603322110878
3. Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the Hallmarks
of Cancer. Cancer Cell. (2018) 34:21–43. doi: 10.1016/j.ccell.2018.
03.022
4. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y,
et al. The selective autophagy substrate p62 activates the stress responsive
transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol. (2010)
12:213–23. doi: 10.1038/ncb2021
Frontiers in Oncology | www.frontiersin.org 9 February 2020 | Volume 10 | Article 256
Ippolito et al. Targeting Mitochondrial ROS in Cancer
5. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, et al.
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial
function. Nature. (2014) 514:628–32. doi: 10.1038/nature13611
6. Havas KM, Milchevskaya V, Radic K, Alladin A, Kafkia E, Garcia M, et al.
Metabolic shifts in residual breast cancer drive tumor recurrence. J Clin Invest.
(2017) 127:2091–105. doi: 10.1172/JCI89914
7. De Santis MC, Porporato PE, Martini M, Morandi A. Signaling pathways
regulating redox balance in cancer metabolism. Front Oncol. (2018) 8:126.
doi: 10.3389/fonc.2018.00126
8. Park JS, Sharma LK, Li H, Xiang R, Holstein D, Wu J, et al. A heteroplasmic,
not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via
alteration in reactive oxygen species generation and apoptosis. Hum Mol
Genet. (2009) 18:1578–89. doi: 10.1093/hmg/ddp069
9. van GisbergenMW, Voets AM, Starmans MH, de Coo IF, Yadak R, Hoffmann
RF, et al. How do changes in the mtDNA and mitochondrial dysfunction
influence cancer and cancer therapy? Challenges, opportunities and models.
Mutat Res Rev Mutat Res. (2015) 764:16–30. doi: 10.1016/j.mrrev.2015.01.001
10. Woo DK, Green PD, Santos JH, D’Souza AD, Walther Z, Martin WD,
et al. Mitochondrial genome instability and ROS enhance intestinal
tumorigenesis in APC(Min/+) mice. Am J Pathol. (2012) 180:24–31.
doi: 10.1016/j.ajpath.2011.10.003
11. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi
H, et al. ROS-generating mitochondrial DNA mutations can regulate tumor
cell metastasis. Science. (2008) 320:661–4. doi: 10.1126/science.1156906
12. Bartesaghi S, Graziano V, Galavotti S, Henriquez NV, Betts J, Saxena J,
et al. Inhibition of oxidative metabolism leads to p53 genetic inactivation
and transformation in neural stem cells. Proc Natl Acad Sci USA. (2015)
112:1059–64. doi: 10.1073/pnas.1413165112
13. Kenny TC, Craig AJ, Villanueva A, Germain D. Mitohormesis primes
tumor invasion and metastasis. Cell Rep. (2019) 27:2292–303.e6.
doi: 10.1016/j.celrep.2019.04.095
14. Guzy RD, Sharma B, Bell E, Chandel NS, Schumacker PT. Loss of the SdhB,
but not the SdhA, subunit of complex II triggers reactive oxygen species-
dependent hypoxia-inducible factor activation and tumorigenesis. Mol Cell
Biol. (2008) 28:718–31. doi: 10.1128/MCB.01338-07
15. Sullivan LB, Martinez-Garcia E, Nguyen H, Mullen AR, Dufour E,
Sudarshan S, et al. The proto-oncometabolite fumarate binds glutathione
to amplify ROS-dependent signaling. Mol Cell. (2013) 51:236–48.
doi: 10.1016/j.molcel.2013.05.003
16. Molenaar RJ, Botman D, Smits MA, Hira VV, van Lith SA, Stap
J, et al. Radioprotection of IDH1-mutated cancer cells by the
IDH1-mutant inhibitor AGI-5198. Cancer Res. (2015) 75:4790–802.
doi: 10.1158/0008-5472.CAN-14-3603
17. Mills EL, Kelly B, Logan A, Costa ASH, Varma M, Bryant CE, et al.
Succinate dehydrogenase supports metabolic repurposing of mitochondria
to drive inflammatory macrophages. Cell. (2016) 167:457–70.e13.
doi: 10.1016/j.cell.2016.08.064
18. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG,
Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis
by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. (2005) 7:77–85.
doi: 10.1016/j.ccr.2004.11.022
19. Hamanaka RB, Chandel NS. Mitochondrial reactive oxygen species
regulate hypoxic signaling. Curr Opin Cell Biol. (2009) 21:894–9.
doi: 10.1016/j.ceb.2009.08.005
20. Chen CL, Uthaya Kumar DB, Punj V, Xu J, Sher L, Tahara SM, et al.
NANOG metabolically reprograms tumor-initiating stem-like cells through
tumorigenic changes in oxidative phosphorylation and fatty acid metabolism.
Cell Metab. (2016) 23:206–19. doi: 10.1016/j.cmet.2015.12.004
21. Pastò A, Bellio C, Pilotto G, Ciminale V, Silic-Benussi M, Guzzo G, et al.
Cancer stem cells from epithelial ovarian cancer patients privilege oxidative
phosphorylation, and resist glucose deprivation. Oncotarget. (2014) 5:4305–
19. doi: 10.18632/oncotarget.2010
22. Wang C, Shao L, Pan C, Ye J, Ding Z, Wu J, et al. Elevated level of
mitochondrial reactive oxygen species via fatty acid β-oxidation in cancer
stem cells promotes cancer metastasis by inducing epithelial-mesenchymal
transition. Stem Cell Res Ther. (2019) 10:175. doi: 10.1186/s13287-019-1265-2
23. Sancho P, Barneda D, Heeschen C. Hallmarks of cancer stem cell metabolism.
Br J Cancer. (2016) 114:1305–12. doi: 10.1038/bjc.2016.152
24. Fan S, Tian T, Chen W, Lv X, Lei X, Zhang H, et al. Mitochondrial
miRNA determines chemoresistance by reprogramming metabolism and
regulating mitochondrial transcription. Cancer Res. (2019) 79:1069–84.
doi: 10.1158/0008-5472.CAN-18-2505
25. Gentric G, Kieffer Y, Mieulet V, Goundiam O, Bonneau C, Nemati F, et al.
PML-Regulated mitochondrial metabolism enhances chemosensitivity
in human ovarian cancers. Cell Metab. (2019) 29:156–73.e10.
doi: 10.1016/j.cmet.2018.09.002
26. Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano
AL, Hutchinson KE, et al. MYC and MCL1 cooperatively promote
chemotherapy-resistant breast cancer stem cells via regulation of
mitochondrial oxidative phosphorylation. Cell Metab. (2017) 26:633–47.e7.
doi: 10.1016/j.cmet.2017.09.009
27. Sancho P, Burgos-Ramos E, Tavera A, Bou Kheir T, Jagust P, Schoenhals
M, et al. MYC/PGC-1α balance determines the metabolic phenotype and
plasticity of pancreatic cancer stem cells. Cell Metab. (2015) 22:590–605.
doi: 10.1016/j.cmet.2015.08.015
28. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, et al.
Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix
attachment. Nature. (2009) 461:109–13. doi: 10.1038/nature08268
29. Kamarajugadda S, Stemboroski L, Cai Q, Simpson NE, Nayak S, Tan M, et al.
Glucose oxidation modulates anoikis and tumor metastasis. Mol Cell Biol.
(2012) 32:1893–907. doi: 10.1128/MCB.06248-11
30. Jiang L, Shestov AA, Swain P, Yang C, Parker SJ, Wang QA, et al. Reductive
carboxylation supports redox homeostasis during anchorage-independent
growth. Nature. (2016) 532:255–8. doi: 10.1038/nature17393
31. Labuschagne CF, Cheung EC, Blagih J, Domart MC, Vousden KH.
Cell clustering promotes a metabolic switch that supports metastatic
colonization. Cell Metab. (2019) 30:720–34.e5. doi: 10.1016/j.cmet.2019.
07.014
32. Di Marcantonio D, Martinez E, Sidoli S, Vadaketh J, Nieborowska-Skorska M,
Gupta A, et al. Protein kinase C epsilon is a key regulator of mitochondrial
redox homeostasis in acute myeloid leukemia.Clin Cancer Res. (2018) 24:608–
18. doi: 10.1158/1078-0432.CCR-17-2684
33. Ye J, Fan J, Venneti S, Wan YW, Pawel BR, Zhang J, et al. Serine catabolism
regulates mitochondrial redox control during hypoxia. Cancer Discov. (2014)
4:1406–17. doi: 10.1158/2159-8290.CD-14-0250
34. Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z,
et al. Oxidative stress inhibits distant metastasis by human melanoma cells.
Nature. (2015) 527:186–91. doi: 10.1038/nature15726
35. Porporato PE, Payen VL, Pérez-Escuredo J, De Saedeleer CJ, Danhier P,
Copetti T, et al. A mitochondrial switch promotes tumor metastasis. Cell Rep.
(2014) 8:754–66. doi: 10.1016/j.celrep.2014.06.043
36. Vazquez F, Lim JH, Chim H, Bhalla K, Girnun G, Pierce K, et al. PGC1α
expression defines a subset of human melanoma tumors with increased
mitochondrial capacity and resistance to oxidative stress. Cancer Cell. (2013)
23:287–301. doi: 10.1016/j.ccr.2012.11.020
37. LaGory EL, Wu C, Taniguchi CM, Ding CC, Chi JT, von Eyben R,
et al. Suppression of PGC-1α is critical for reprogramming oxidative
metabolism in renal cell carcinoma. Cell Rep. (2015) 12:116–27.
doi: 10.1016/j.celrep.2015.06.006
38. Torrano V, Valcarcel-Jimenez L, Cortazar AR, Liu X, Urosevic J, Castillo-
MartinM, et al. Themetabolic co-regulator PGC1α suppresses prostate cancer
metastasis. Nat Cell Biol. (2016) 18:645–56. doi: 10.1038/ncb3357
39. Bacci M, Ippolito L, Magnelli L, Giannoni E, Chiarugi P. Stromal-
induced mitochondrial re-education: impact on epithelial-to-mesenchymal
transition and cancer aggressiveness. Semin Cell Dev Biol. (2020) 98:71–9.
doi: 10.1016/j.semcdb.2019.05.009
40. Dong LF, Kovarova J, Bajzikova M, Bezawork-Geleta A, Svec D, Endaya
B, et al. Horizontal transfer of whole mitochondria restores tumorigenic
potential in mitochondrial DNA-deficient cancer cells. Elife. (2017) 6:e22187.
doi: 10.7554/eLife.22187
41. Ippolito L, Morandi A, Taddei ML, Parri M, Comito G, Iscaro A,
et al. Cancer-associated fibroblasts promote prostate cancer malignancy via
metabolic rewiring and mitochondrial transfer. Oncogene. (2019) 38:5339–55.
doi: 10.1038/s41388-019-0805-7
42. Giannoni E, Taddei ML, Morandi A, Comito G, Calvani M, Bianchini F, et al.
Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs
Frontiers in Oncology | www.frontiersin.org 10 February 2020 | Volume 10 | Article 256
Ippolito et al. Targeting Mitochondrial ROS in Cancer
oxphos and prostate cancer metastatic spread.Oncotarget. (2015) 6:24061–74.
doi: 10.18632/oncotarget.4448
43. Shimura T, Sasatani M, Kawai H, Kamiya K, Kobayashi J, Komatsu
K, et al. Radiation-induced myofibroblasts promote tumor growth via
mitochondrial ROS-activated TGFβ signaling. Mol Cancer Res. (2018)
16:1676–86. doi: 10.1158/1541-7786.MCR-18-0321
44. Rice CM, Davies LC, Subleski JJ, Maio N, Gonzalez-CottoM, Andrews C, et al.
Tumour-elicited neutrophils engagemitochondrial metabolism to circumvent
nutrient limitations and maintain immune suppression. Nat Commun. (2018)
9:5099. doi: 10.1038/s41467-018-07505-2
45. Pacella I, Procaccini C, Focaccetti C, Miacci S, Timperi E, Faicchia D, et al.
Fatty acid metabolism complements glycolysis in the selective regulatory
T cell expansion during tumor growth. Proc Natl Acad Sci USA. (2018)
115:E6546–555. doi: 10.1073/pnas.1720113115
46. Kunisada Y, Eikawa S, Tomonobu N, Domae S, Uehara T, Hori
S, et al. Attenuation of CD4. EBioMedicine. (2017) 25:154–64.
doi: 10.1016/j.ebiom.2017.10.009
47. Weinberg SE, Singer BD, Steinert EM, Martinez CA, Mehta MM, Martínez-
Reyes I, et al. Mitochondrial complex III is essential for suppressive function of
regulatory T cells. Nature. (2019) 565:495–9. doi: 10.1038/s41586-018-0846-z
48. Maj T, Wang W, Crespo J, Zhang H, Wei S, Zhao L, et al. Oxidative
stress controls regulatory T cell apoptosis and suppressor activity and
PD-L1-blockade resistance in tumor. Nat Immunol. (2017) 18:1332–41.
doi: 10.1038/ni.3868
49. Chang CH, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD, et al.
Metabolic competition in the tumor microenvironment is a driver of cancer
progression. Cell. (2015) 162:1229–41. doi: 10.1016/j.cell.2015.08.016
50. Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC,
et al. The tumor microenvironment represses T cell mitochondrial biogenesis
to drive intratumoral T cell metabolic insufficiency and dysfunction.
Immunity. (2016) 45:374–88. doi: 10.1016/j.immuni.2016.07.009
51. Sena LA, Li S, Jairaman A, Prakriya M, Ezponda T, Hildeman DA,
et al. Mitochondria are required for antigen-specific T cell activation
through reactive oxygen species signaling. Immunity. (2013) 38:225–36.
doi: 10.1016/j.immuni.2012.10.020
52. Siska PJ, Beckermann KE, Mason FM, Andrejeva G, Greenplate AR,
Sendor AB, et al. Mitochondrial dysregulation and glycolytic insufficiency
functionally impair CD8T cells infiltrating human renal cell carcinoma. JCI
Insight. (2017) 2:e93411. doi: 10.1172/jci.insight.93411
53. De Saedeleer CJ, Porporato PE, Copetti T, Pérez-Escuredo J, PayenVL, Brisson
L, et al. Glucose deprivation increases monocarboxylate transporter 1 (MCT1)
expression and MCT1-dependent tumor cell migration. Oncogene. (2014)
33:4060–8. doi: 10.1038/onc.2013.454
54. Dashdorj A, Jyothi KR, Lim S, Jo A, Nguyen MN, Ha J, et al. Mitochondria-
targeted antioxidant MitoQ ameliorates experimental mouse colitis by
suppressing NLRP3 inflammasome-mediated inflammatory cytokines. BMC
Med. (2013) 11:178. doi: 10.1186/1741-7015-11-178
55. Formentini L, Santacatterina F, Núñez de Arenas C, Stamatakis K, López-
Martínez D, Logan A, et al. Mitochondrial ROS production protects the
intestine from inflammation through functionalM2macrophage polarization.
Cell Rep. (2017) 19:1202–13. doi: 10.1016/j.celrep.2017.04.036
56. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V,
et al. Functional polarization of tumour-associated macrophages by tumour-
derived lactic acid. Nature. (2014) 513:559–63. doi: 10.1038/nature13490
57. Lin X, Zheng W, Liu J, Zhang Y, Qin H, Wu H, et al. Oxidative stress in
malignant melanoma enhances tumor necrosis factor-α secretion of tumor-
associated macrophages that promote cancer cell invasion. Antioxid Redox
Signal. (2013) 19:1337–55. doi: 10.1089/ars.2012.4617
58. Oberkampf M, Guillerey C, Mouriès J, Rosenbaum P, Fayolle C, Bobard A,
et al. Mitochondrial reactive oxygen species regulate the induction of CD8.
Nat Commun. (2018) 9:2241. doi: 10.1038/s41467-018-04686-8
59. Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer
therapy. Nat Chem Biol. (2015) 11:9–15. doi: 10.1038/nchembio.1712
60. Bober P, Alexovic M, Talian I, Tomkova Z, Viscorova Z, Benckova M, et al.
Proteomic analysis of the vitamin C effect on the doxorubicin cytotoxicity in
the MCF-7 breast cancer cell line. J Cancer Res Clin Oncol. (2017) 143:35–42.
doi: 10.1007/s00432-016-2259-4
61. Printz C. High vitamin D levels increase survival rates in patients with
metastatic colorectal cancer.Cancer. (2015) 121:2105. doi: 10.1002/cncr.29513
62. Harris HR, Orsini N, Wolk A. Vitamin C and survival among women
with breast cancer: a meta-analysis. Eur J Cancer. (2014) 50:1223–31.
doi: 10.1016/j.ejca.2014.02.013
63. Chandel NS, Tuveson DA. The promise and perils of antioxidants for
cancer patients. N Engl J Med. (2014) 371:177–8. doi: 10.1056/NEJMcibr1
405701
64. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by
conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol. (2007)
47:629–56. doi: 10.1146/annurev.pharmtox.47.120505.105110
65. JinH, KanthasamyA, GhoshA, AnantharamV, Kalyanaraman B, Kanthasamy
AG. Mitochondria-targeted antioxidants for treatment of Parkinson’s disease:
preclinical and clinical outcomes. Biochim Biophys Acta. (2014) 1842:1282–94.
doi: 10.1016/j.bbadis.2013.09.007
66. Izyumov DS, Domnina LV, Nepryakhina OK, Avetisyan AV, Golyshev
SA, Ivanova OY, et al. Mitochondria as source of reactive oxygen
species under oxidative stress. Study with novel mitochondria-targeted
antioxidants–the “Skulachev-ion” derivatives. Biochemistry. (2010) 75:123–9.
doi: 10.1134/s000629791002001x
67. Bendell JC, Patel MR, Infante JR, Kurkjian CD, Jones SF, Pant S, et al. Phase
1, open-label, dose escalation, safety, and pharmacokinetics study of ME-
344 as a single agent in patients with refractory solid tumors. Cancer. (2015)
121:1056–63. doi: 10.1002/cncr.29155
68. Cheng G, Zielonka J, Ouari O, Lopez M, McAllister D, Boyle K,
et al. Mitochondria-targeted analogues of metformin exhibit enhanced
antiproliferative and radiosensitizing effects in pancreatic cancer cells. Cancer
Res. (2016) 76:3904–15. doi: 10.1158/0008-5472.CAN-15-2534
69. Cheng G, Zielonka J, McAllister DM, Mackinnon AC, Joseph J, Dwinell
MB, et al. Mitochondria-targeted vitamin E analogs inhibit breast cancer
cell energy metabolism and promote cell death. BMC Cancer. (2013) 13:285.
doi: 10.1186/1471-2407-13-285
70. Cheng G, Zielonka J, McAllister D, Hardy M, Ouari O, Joseph J, et al.
Antiproliferative effects of mitochondria-targeted cationic antioxidants and
analogs: role of mitochondrial bioenergetics and energy-sensing mechanism.
Cancer Lett. (2015) 365:96–106. doi: 10.1016/j.canlet.2015.05.016
71. Verrax J, Cadrobbi J, Marques C, Taper H, Habraken Y, Piette J, et al.
Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative
stress that kills cancer cells by a non-apoptotic caspase-3 independent form
of cell death. Apoptosis. (2004) 9:223–33. doi: 10.1023/B:APPT.0000018804.
26026.1a
72. Dong LF, Low P, Dyason JC, Wang XF, Prochazka L, Witting PK, et al. Alpha-
tocopheryl succinate induces apoptosis by targeting ubiquinone-binding
sites in mitochondrial respiratory complex II. Oncogene. (2008) 27:4324–35.
doi: 10.1038/onc.2008.69
73. Stacpoole PW. Therapeutic targeting of the pyruvate dehydrogenase
complex/pyruvate dehydrogenase kinase (PDC/PDK) axis in cancer. J Natl
Cancer Inst. (2017) 109:djx071. doi: 10.1093/jnci/djx071
74. Nazarewicz RR, Dikalova A, Bikineyeva A, Ivanov S, Kirilyuk IA, Grigor’ev
IA, et al. Does scavenging of mitochondrial superoxide attenuate cancer
prosurvival signaling pathways? Antioxid Redox Signal. (2013) 19:344–9.
doi: 10.1089/ars.2013.5185
75. Titova E, Shagieva G, Ivanova O, Domnina L, Domninskaya M, Strelkova
O, et al. Mitochondria-targeted antioxidant SkQ1 suppresses fibrosarcoma
and rhabdomyosarcoma tumour cell growth. Cell Cycle. (2018) 17:1797–811.
doi: 10.1080/15384101.2018.1496748
76. Guimarães TA, Farias LC, Santos ES, de Carvalho C, Fraga A, Orsini LA, et al.
Metformin increases PDH and suppresses HIF-1α under hypoxic conditions
and induces cell death in oral squamous cell carcinoma. Oncotarget. (2016)
7:55057–68. doi: 10.18632/oncotarget.10842
77. Grassian AR, Parker SJ, Davidson SM, Divakaruni AS, Green CR, Zhang
X, et al. IDH1 mutations alter citric acid cycle metabolism and increase
dependence on oxidative mitochondrial metabolism. Cancer Res. (2014)
74:3317–31. doi: 10.1158/0008-5472.CAN-14-0772-T
78. Anso E, Mullen AR, Felsher DW, Matés JM, Deberardinis RJ, Chandel NS.
Metabolic changes in cancer cells upon suppression of MYC. Cancer Metab.
(2013) 1:7. doi: 10.1186/2049-3002-1-7
Frontiers in Oncology | www.frontiersin.org 11 February 2020 | Volume 10 | Article 256
Ippolito et al. Targeting Mitochondrial ROS in Cancer
79. Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, et al.
Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad
Sci USA. (2011) 108:16062–7. doi: 10.1073/pnas.1106704108
80. Verrax J, Delvaux M, Beghein N, Taper H, Gallez B, Buc Calderon P.
Enhancement of quinone redox cycling by ascorbate induces a caspase-3
independent cell death in human leukaemia cells. An in vitro comparative
study. Free Radic Res. (2005) 39:649–57. doi: 10.1080/107157605000
97906
81. Verrax J, Stockis J, Tison A, Taper HS, Calderon PB. Oxidative stress by
ascorbate/menadione association kills K562 human chronic myelogenous
leukaemia cells and inhibits its tumour growth in nude mice. Biochem
Pharmacol. (2006) 72:671–80. doi: 10.1016/j.bcp.2006.05.025
82. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, et al.
Selective killing of oncogenically transformed cells through a ROS-mediated
mechanism by beta-phenylethyl isothiocyanate. Cancer Cell. (2006) 10:241–
52. doi: 10.1016/j.ccr.2006.08.009
83. Locasale JW. Serine glycine and one-carbon units: cancer metabolism in full
circle. Nat Rev Cancer. (2013) 13:572–83. doi: 10.1038/nrc3557
84. Woo CC, Chen WC, Teo XQ, Radda GK, Lee PT. Downregulating
serine hydroxymethyltransferase 2 (SHMT2) suppresses tumorigenesis
in human hepatocellular carcinoma. Oncotarget. (2016) 7:53005–17.
doi: 10.18632/oncotarget.10415
85. Nilsson R, Jain M, Madhusudhan N, Sheppard NG, Strittmatter L, Kampf C,
et al. Metabolic enzyme expression highlights a key role for MTHFD2 and
the mitochondrial folate pathway in cancer. Nat Commun. (2014) 5:3128.
doi: 10.1038/ncomms4128
86. Tobe R, Carlson BA, Tsuji PA, Lee BJ, Gladyshev VN, Hatfield DL. Differences
in redox regulatory systems in human lung and liver tumors suggest different
avenues for therapy. Cancers. (2015) 7:2262–76. doi: 10.3390/cancers7040889
87. Chen Y, Zhang H, Zhou HJ, Ji W, Min W. Mitochondrial redox
signaling and tumor progression. Cancers. (2016) 8:40. doi: 10.3390/cancers8
040040
88. Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC, et al. Glutathione
and thioredoxin antioxidant pathways synergize to drive cancer initiation
and progression. Cancer Cell. (2015) 27:211–22. doi: 10.1016/j.ccell.2014.
11.019
89. Fink EE, Mannava S, Bagati A, Bianchi-Smiraglia A, Nair JR, Moparthy
K, et al. Mitochondrial thioredoxin reductase regulates major cytotoxicity
pathways of proteasome inhibitors in multiple myeloma cells. Leukemia.
(2016) 30:104–11. doi: 10.1038/leu.2015.190
90. Lillig CH, Lönn ME, Enoksson M, Fernandes AP, Holmgren A. Short
interfering RNA-mediated silencing of glutaredoxin 2 increases the sensitivity
of HeLa cells toward doxorubicin and phenylarsine oxide. Proc Natl Acad Sci
USA. (2004) 101:13227–32. doi: 10.1073/pnas.0401896101
91. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a
common denominator approach to cancer therapy. Cancer Cell. (2015)
27:450–61. doi: 10.1016/j.ccell.2015.03.001
92. Chamoto K, Chowdhury PS, Kumar A, Sonomura K, Matsuda F, Fagarasan S,
et al. Mitochondrial activation chemicals synergize with surface receptor PD-
1 blockade for T cell-dependent antitumor activity. Proc Natl Acad Sci USA.
(2017) 114:E761–70. doi: 10.1073/pnas.1620433114
93. Hou XS, Wang HS, Mugaka BP, Yang GJ, Ding Y. Mitochondria: promising
organelle targets for cancer diagnosis and treatment. Biomater Sci. (2018)
6:2786–97. doi: 10.1039/c8bm00673c
94. Jung HS, Lee JH, Kim K, Koo S, Verwilst P, Sessler JL, et al. A mitochondria-
targeted cryptocyanine-based photothermogenic photosensitizer. J Am Chem
Soc. (2017) 139:9972–8. doi: 10.1021/jacs.7b04263
95. Jung HS, Han J, Lee JH, Choi JM, Kweon HS, Han JH, et al. Enhanced NIR
radiation-triggered hyperthermia by mitochondrial targeting. J Am Chem Soc.
(2015) 137:3017–23. doi: 10.1021/ja5122809
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Ippolito, Giannoni, Chiarugi and Parri. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Oncology | www.frontiersin.org 12 February 2020 | Volume 10 | Article 256
